Scribe and Sanofi Expand Collaboration Further to Advance Genetic Treatments
18 July 2023
Collaborations, Mergers & Acquisitions
Scribe Therapeutics expands collaboration with Sanofi to propel a new influx of in vivo genetic medicines for sickle cell and other genomic diseases. The in vivo collaboration leverages Scribe’s CRISPR XE technologies and Sanofi’s capabilities in non-viral delivery to combat sickle cell disease.
“We are continually impressed by the expertise, rigor, and urgency that Sanofi has brought to our existing ex vivo collaboration, as well as their rapid advancements and innovation in non-viral delivery technologies. Now, we are thrilled to expand our work together into new areas of high unmet need,” said Benjamin Oakes, Ph.D., co-founder and CEO of Scribe.
The Companies’ existing collaboration focused on cancer treatment using ex vivo editing of natural killer cell therapies. Under the terms of the agreement, Scribe will receive an upfront payment of $40 million and is eligible to potentially receive more than $1.2 billion based on the successful completion of certain development and sales targets.
The in vivo collaboration leverages Scribe’s CRISPR XE technologies and Sanofi’s capabilities in non-viral delivery to combat sickle cell disease. Scribe’s CRISPR by Design™ powers the only platform that uses holistic engineering to transform bacterial immune systems genome editing technologies suitable for advanced therapies.
“This in vivo collaboration further demonstrates the versatility of Scribe’s design-based approaches to CRISPR, which enable greater activity, specificity, and deliverability, ultimately accelerating the development of life-changing therapeutics,” added Oakes.
Scribe’s tools for in vivo genome editing uses an innovative approach with the potential to minimize complication associated with investigational ex vivo autologous treatments such as conditioning regimen toxicities.
“We’re encouraged by what we’ve accomplished to date with Scribe in creating ex vivo NK cell therapies and now look forward to accelerating our ability to effectively leverage genome editing in vivo through Sanofi’s innovative research work in targeted lipid nanoparticles (LNPs), for in vivo therapies with the potential to dramatically improve treatment outcomes and ultimately to change patients’ lives,” commented Christian Mueller, Global Head of Genomic Medicine Unit at Sanofi.